CDE ID | CDE Description | * 1063 | Site Participant ID (Go To: 422) |
* 422 | EDRN Site ID (Go To: 423) |
* 423 | EDRN Protocol ID (Go To: 1219) |
* 1219 | Date of contact (MM/DD/YYYY): (Go To: 2733) |
2733 | Proposed study group (Go To: 1216) |
| Permissible Values (value): | Set C Cases: Lung cancer (prospective) (21) |
|
| | Set C Controls: High Risk (prospective) (23) |
|
| | Set C Controls: Other cancers (prospective) (25) |
|
1216 | Date of diagnosis of lung cancer (histological or cytopathological report) (MM/DD/YYYY): (Go To: 1220) |
1220 | Disease status: (Go To: 1302) |
| Permissible Values (value): | Relapsed (1) |
|
| |
| |
| |
| |
| |
| | No evidence of disease (7) |
|
| |
1302 | Age at diagnosis (Go To: 1338) |
1338 | Histologic confirmation? (Go To: 1257) |
| Permissible Values (value): | No (0) |
|
| |
1257 | Histologic type (lung): (Go To: 720) |
| Permissible Values (value): | Squamous cell carcinoma (1) |
|
| | Papillary squamous cell carcinoma (2) |
|
| | Clear cell squamous cell carcinoma (3) |
|
| | Small cell squamous cell carcinoma (4) |
|
| | Basaloid squamous cell carcinoma (5) |
|
| |
| | Combined small cell carcinoma (7) |
|
| |
| | Acinar adenocarcinoma (9) |
|
| | Papillary adenocarcinoma (10) |
|
| | Bronchioloalveolar carcinoma (11) |
|
| |
| |
| | Mixed mucinous and non-mucinous or indeterminate (14) |
|
| | Solid adenocarcinoma with mucin formation (15) |
|
| | Adenocarcinoma with mixed subtypes (16) |
|
| | Large cell carcinoma (17) |
|
| |
| |
720 | Anatomical site (Go To: 1241) |
| Permissible Values (value): | Bladder (1) |
|
| |
| | Bowel peritoneum/serosa (3) |
|
| |
| |
| |
| |
| |
| |
| |
| |
| | Peritoneum/uterine serosa (12) |
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| | Responses are organ-specific (999) |
|
1241 | Histologic dimensions - height (cm): (Go To: 1242) |
1242 | Histologic dimensions - width (cm): (Go To: 1243) |
1243 | Histologic dimensions - depth (cm): (Go To: 1244) |
1244 | Histologic dimensions - volume (ml): (Go To: 1245) |
1245 | Distance/pleural margin (mm): (Go To: 1246) |
1246 | Distance/bronchial margin (mm): (Go To: 786) |
786 | Lung T-Stage, Pathologic (Go To: 789) |
| Permissible Values (value): | pTX (1) |
|
| |
| |
| |
| |
| |
| |
789 | Lung N-Stage, Pathologic (Go To: 790) |
| Permissible Values (value): | pNX (1) |
|
| |
| |
| |
| |
790 | Lung M-Stage, Pathologic (Go To: 785) |
| Permissible Values (value): | pMX (1) |
|
| |
| |
785 | Lung T-Stage, Clinical (Go To: 787) |
| Permissible Values (value): | TX (1) |
|
| |
| |
| |
| |
| |
| |
787 | Lung N-Stage, Clinical (Go To: 788) |
| Permissible Values (value): | NX (1) |
|
| |
| |
| |
| |
788 | Lung M-Stage, Clinical (Go To: 1240) |
| Permissible Values (value): | MX (1) |
|
| |
| |
1240 | Reported adenopathy > 1 cm in the mediastinum at time of diagnosis? (Go To: 1266) |
| Permissible Values (value): | No (0) |
|
| |
| |
1266 | Other lung diseases participant has: (Go To: 2148) |
| Permissible Values (value): | COPD (1) |
|
| |
| |
| |
| |
| |
| |
2148 | Primary cancer treatment(s) received: (Go To: 1258) |
| Permissible Values (value): | Chemotherapy (1) |
|
| |
| |
| |
| |
| | LHRH agonists or anti-androgens hormone therapy (6) |
|
| |
| |
| |
| |
1258 | Chemotherapy treatment(s) received: [specify drug(s)] (Go To: 1259) |
1259 | Chemotherapy start date (MM/YYYY): (Go To: 1260) |
1260 | Chemotherapy end date (MM/YYYY): (Go To: 1261) |
1261 | Radiation therapy received: (specify site) (Go To: 1262) |
1262 | Radiation therapy start date: (MM/YYYY): (Go To: 1263) |
1263 | Radiation therapy end date: (MM/YYYY): (Go To: 1264) |
1264 | Total dose to chest: (cGy) (Go To: 1265) |
1265 | Total dose to other organ(s): (cGy) (Go To: 1282) |
1282 | Radiation therapy (RT) volume [cubic mm]: (Go To: 1281) |
1281 | Radiation therapy (RT) complications: (Go To: 1279) |
| Permissible Values (value): | Pneumonitis requiring steroids (1) |
|
| | Esophagitis requiring IVF (2) |
|
| |
| |
| |
1279 | Response to treatment (imaging criteria) (Go To: 1278) |
| Permissible Values (value): | No (0) |
|
| |
1278 | Date of response (MM/DD/YYYY): (Go To: 1280) |
1280 | Overall survival (OS) in days: (Go To: 1272) |
1272 | Living status: (Go To: 1218) |
| Permissible Values (value): | Alive with disease (1) |
|
| | Alive with no evidence of disease (NED) (2) |
|
| |
| |
1218 | Last date known alive (MM/DD/YYYY): (Go To: 1336) |
1336 | Date of death (MM/DD/YYYY): (Go To: 1332) |
1332 | Cause of death: (Go To: 1271) |
1271 | Comorbidities: (Go To: 1097) |
| Permissible Values (value): | Myocardial infarction (1) |
|
| | Congestive heart failure (2) |
|
| | Peripheral vascular disease (3) |
|
| | Cerebrovascular disease (4) |
|
| |
| | Chronic pulmonary disease (6) |
|
| | Connective tissue disease (7) |
|
| |
| |
| |
| |
| | Moderate or severe renal disease (12) |
|
| | Diabetes with end organ damage (13) |
|
| | Moderate or severe liver disease (14) |
|
| | Metastatic solid tumor (15) |
|
| |
1097 | Comments (do not include any participant identifiers) (Go To: End of Form) |